Scilex Holding Company(SCLX)Earnings, Financials & Key RatiosScilex Holding Company (SCLX) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to maintain positive free cash flow, evidenced by a $4.2 million burn in 2026Q1, combined with a current ratio of 0.08, indicates an imminent risk of insolvency.
Scilex Holding Company (SCLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Scilex Holding Company (SCLX) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $4.76vs $0.34-1311.2% | $9Mvs $15M-42.6% |
| Q2 2026 | Apr 10, 2026 | $4.60vs $0.47-878.7% | $5Mvs $12M-60.4% |
| Q4 2025 | Nov 14, 2025 | $22.17vs $0.47-4617.0% | $11Mvs $12M-12.7% |
| Q3 2025 | Aug 13, 2025 | $7.42vs $0.41-1709.8% | $10Mvs $26M-62.3% |
Recent stock market news and headlines for Scilex Holding Company (SCLX)
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million) Scilex (NASDAQ: SCLX) Loan Substantially Repaid Total Cash and Assets Build to Approximately $270 Million (as of March 31, 2026, after the $10.5 million dividend paid in January 2026) Oramed to Join the Russell 2000 and Russell 3000 Indexes this week NEW YORK, June 25, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the following Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. The letter highlights the Company's addition to the Russell 2000 and Russell 3000 indexes, the substantial repayment of its Scilex loan, and a strengthened balance sheet of approximately $270 million in total cash and assets, as of March 31, 2026 (unaudited).
PALO ALTO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced Dream Bowl I Meme Coin tokens (“Dream Bowl Tokens”) to list on Biconomy Exchange as early as June 23, 2026.
Key metrics vs top competitors for Scilex Holding Company (SCLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.07 | $68.52M | -0.22 | -46.54% | -1185.78% | — | — | |
| $34.13 | $1.38B | 28.68 | 27.37% | 6.35% | 29.49% | — | |
| $37.01 | $2.14B | 13.66 | 21.51% | 16.2% | 17.19% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $37.47 | $1.22B | 21.66 | 23.62% | 9.41% | 26.74% | — |
Scilex Holding Company (SCLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Scilex Holding Company (SCLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
May 5, 2026·SEC
Apr 28, 2026·SEC
Get notified when SCLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Scilex Holding Company (SCLX) stock FAQ — growth, dividends, profitability & financials explained
Scilex Holding Company (SCLX) reported $33.9M in revenue for fiscal year 2025. This represents a 44% increase from $23.6M in 2020.
Scilex Holding Company (SCLX) saw revenue decline by 46.5% over the past year.
Scilex Holding Company (SCLX) reported a net loss of $419.7M for fiscal year 2025.
Scilex Holding Company (SCLX) had negative free cash flow of $6.6M in fiscal year 2025, likely due to heavy capital investments.
